Financing repurposed drugs for rare diseases: a case study of Unravel Biosciences.

Abouarab B, Bazarian C, Ben Chaouch Z, Lo AW, Mourenza Gonzalez G, Novak R, Vigneault F

Open source

DOI
10.1186/s13023-023-02753-y
Published
2023 Sep 12
Container
Orphanet journal of rare diseases
Publisher
Not recorded
Open access
yes

Credibility signals

limited evidence Score 45/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

Cite this work

BibTeX

@article{allodium:10.1186/s13023-023-02753-y,
  title = {Financing repurposed drugs for rare diseases: a case study of Unravel Biosciences.},
  author = {Abouarab B and Bazarian C and Ben Chaouch Z and Lo AW and Mourenza Gonzalez G and Novak R and Vigneault F},
  year = {2023},
  journal = {Orphanet journal of rare diseases},
  doi = {10.1186/s13023-023-02753-y},
  url = {https://doi.org/10.1186/s13023-023-02753-y}
}

RIS

TY  - JOUR
TI  - Financing repurposed drugs for rare diseases: a case study of Unravel Biosciences.
AU  - Abouarab B
AU  - Bazarian C
AU  - Ben Chaouch Z
AU  - Lo AW
AU  - Mourenza Gonzalez G
AU  - Novak R
AU  - Vigneault F
PY  - 2023
JO  - Orphanet journal of rare diseases
DO  - 10.1186/s13023-023-02753-y
UR  - https://doi.org/10.1186/s13023-023-02753-y
ER  - 

APA

B, A., C, B., Z, B. C., AW, L., G, M. G., R, N., & F, V. (2023). Financing repurposed drugs for rare diseases: a case study of Unravel Biosciences.. Orphanet journal of rare diseases. https://doi.org/10.1186/s13023-023-02753-y

Source records